Compounded vs Branded GLP-1 Cost Calculator

How much you've already spent on compounded — and what changes if FDA finalizes the 503B exclusion. Three quick questions.

The 503B comment period closes June 29, 2026

The FDA proposed adding semaglutide, tirzepatide, and liraglutide to the 503B Bulks list — which would close the compounded telehealth path for these molecules. This calculator shows your current lifetime spend, your branded baseline, and what your next 12 months would cost if the ban finalizes.

Which medication are you on (or considering)?

Pricing is directional, not a quote

Compounded prices vary by telehealth provider; branded prices vary by plan, deductible, pharmacy, and dose. May 2026 averages are used here. The FDA 503B Bulks proposal is in the comment period and not finalized. This tool is informational, not medical or financial or legal advice.

What This Calculator Compares

Compounded GLP-1 medications — semaglutide, tirzepatide, liraglutide — sold through cash-pay telehealth platforms typically run $200–$250/month, while branded versions (Ozempic, Mounjaro, Wegovy, Zepbound) list at $1,069–$1,349/month. Manufacturer savings cards bring branded down to $25/month when your plan covers obesity meds, but most plans don't. Lilly Direct sells Zepbound (tirzepatide) vials direct-to-consumer at $349/month for doses 2.5–10mg ($499 for higher doses), no insurance needed. On April 30, 2026 the FDA proposed adding semaglutide, tirzepatide, and liraglutide to the 503B Bulks exclusion list — if finalized after the June 29 comment period closes, large-scale compounded telehealth paths for these molecules would close. This calculator runs your specific numbers across all four paths, shows your lifetime compounded spend so far, and projects the next 12 months under the proposed-ban scenario.

Who Is This For?

Anyone currently on compounded GLP-1 trying to plan for a possible 503B finalization, anyone weighing whether to start on the cheaper compounded path versus a branded path, and anyone who has been on compounded for a while and wants to see lifetime spend in one number. The result is informational — your real cost depends on your specific telehealth provider, your insurance plan, your dose, and your pharmacy. Confirm with your prescriber before changing paths; sudden discontinuation of a GLP-1 can drive weight regain.

Frequently Asked Questions

Is compounded tirzepatide legal?

Compounded tirzepatide and semaglutide are produced by 503A and 503B compounding pharmacies. They are legal under current US law because the FDA has, in the past, declared the branded versions to be in shortage. As of April 30, 2026, the FDA has proposed adding semaglutide, tirzepatide, and liraglutide to the 503B Bulks exclusion list. The proposal is in a public comment period through June 29, 2026. If finalized, large-scale 503B compounding of these molecules would close.

Will compounded GLP-1 be banned?

The FDA has not finalized a ban as of May 2026. The April 30 proposal is in the comment period through June 29, 2026. After comments are reviewed, the FDA can finalize, modify, or withdraw the proposal. A finalized 503B exclusion would close most large-scale compounded telehealth paths for these molecules but would not change 503A patient-specific compounding rules.

Is compounded GLP-1 cheaper than branded?

Yes, usually significantly. Compounded telehealth tirzepatide averages around $250/month and compounded semaglutide around $200/month. Branded list prices are $1,069–$1,349/month, savings card paths are $25/month if your plan covers obesity meds (most do not), and Lilly Direct (Zepbound vials, tirzepatide only, doses 2.5–10 mg) is $349/month for cash pay. Without obesity coverage, compounded is cheaper than every branded path except Lilly Direct vials for some doses.

What happens if FDA bans compounded GLP-1?

If the 503B Bulks exclusion finalizes, large-scale compounded sema, tirz, and lira sold through telehealth would no longer be permitted. Patients on compounded paths would need to transition to a branded path: branded with savings card if your plan covers, branded list price, or Lilly Direct vials for tirzepatide. The realistic baseline cost increase ranges from approximately $250–$400 a month per patient depending on molecule and coverage.

How do I switch from compounded to branded GLP-1?

Talk to your prescriber. The molecule is the same, but a new prescription is needed for the branded version, your insurance prior authorization process resets, and you may need to repeat dose titration if you have been on a non-standard compounded dose. Plan for a 4-8 week transition window. Sudden discontinuation can trigger weight regain.

Does insurance cover compounded GLP-1?

Almost never. Compounded medications generally do not go through PBM formularies and are not covered by commercial insurance. That is part of why they are sold through cash-pay telehealth platforms. Branded GLP-1s — when your plan covers obesity meds — are usually $25/month with the manufacturer savings card. The savings card path is dramatically cheaper than compounded if you qualify.

Save your result

Email yourself a copy and join the weekly Gila newsletter — actionable GLP-1 research, no spam.

I agree to receive the Gila newsletter and understand I can unsubscribe anytime. See the Terms and Privacy Policy.

These tools are for informational purposes only and do not constitute medical advice. Always consult your healthcare provider.